AI-driven drug discovery and synthesis

Exploring gut-brain axis modulation through personalized probiotic interventions in depression treatment

gut-brain axis probiotics depression microbiome neurotransmitter

For senolytic drug discovery using CRISPR-based senescence biomarkers

senolytic drugs CRISPR biomarkers aging research drug discovery cellular senescence

Marrying psychedelic research with neural decoding via fMRI and EEG synchronization

psychedelics neural decoding fMRI EEG brain dynamics

Accelerating antiviral drug discovery via self-supervised curriculum learning for pandemic-ready compounds

self-supervised learning antiviral drugs pandemic response computational chemistry outbreak simulation

Through solvent selection engines for optimizing pharmaceutical crystallization processes

solvent selection pharmaceutical crystallization computational chemistry drug formulation crystal engineering

Using explainability through disentanglement in AI-driven drug discovery

explainable AI drug discovery disentanglement deep learning molecular design

Optimizing flow chemistry robots for high-throughput synthesis of pharmaceutical intermediates

flow chemistry robotics pharmaceutical synthesis high-throughput automation

Engineering viral vectors for targeted epigenetic reprogramming in neurodegenerative therapies

viral vectors epigenetic reprogramming neurodegenerative diseases gene therapy CRISPR

Autonomous lab assistants for accelerating drug discovery with zero-gravity 3D printing

autonomous labs drug discovery zero-gravity 3D printing pharmaceuticals

For epigenetic age reversal via targeted histone demethylation in senescent cells

epigenetic reprogramming senescence reversal histone modification CRISPR aging therapy longevity biotechnology

For senolytic drug discovery targeting age-related cellular dysfunction

senolytics aging biomarkers cellular senescence drug screening geroprotectors

Targeting protein misfolding in neurodegenerative diseases with small-molecule chaperones

protein misfolding neurodegenerative diseases small-molecule chaperones drug discovery amyloid aggregation